Editas Medicine Inc (NASDAQ:EDIT) insider Katrine Bosley sold 14,995 shares of the firm’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $34.15, for a total value of $512,079.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Katrine Bosley also recently made the following trade(s):

  • On Friday, December 1st, Katrine Bosley sold 8,333 shares of Editas Medicine stock. The stock was sold at an average price of $29.58, for a total value of $246,490.14.
  • On Wednesday, November 1st, Katrine Bosley sold 8,333 shares of Editas Medicine stock. The stock was sold at an average price of $23.64, for a total value of $196,992.12.

Shares of Editas Medicine Inc (EDIT) traded up $0.59 during midday trading on Thursday, hitting $33.92. The stock had a trading volume of 1,224,135 shares, compared to its average volume of 1,656,767. The company has a market cap of $1,500.00 and a PE ratio of -10.47. The company has a debt-to-equity ratio of 0.19, a current ratio of 10.12 and a quick ratio of 10.12. Editas Medicine Inc has a 12 month low of $13.12 and a 12 month high of $36.00.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings data on Tuesday, November 7th. The company reported ($0.64) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.04). The company had revenue of $6.28 million during the quarter, compared to the consensus estimate of $2.66 million. Editas Medicine had a negative net margin of 1,127.03% and a negative return on equity of 70.19%. Editas Medicine’s revenue was up 553.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.59) EPS. sell-side analysts anticipate that Editas Medicine Inc will post -2.92 earnings per share for the current fiscal year.

Several analysts recently commented on EDIT shares. Barclays started coverage on Editas Medicine in a research note on Wednesday, September 6th. They set an “overweight” rating and a $28.00 price objective on the stock. ValuEngine upgraded Editas Medicine from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Morgan Stanley reiterated an “equal weight” rating and set a $28.00 target price (up previously from $27.00) on shares of Editas Medicine in a report on Friday, October 6th. Zacks Investment Research cut Editas Medicine from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Finally, Cowen reiterated a “buy” rating on shares of Editas Medicine in a report on Tuesday, November 7th. One analyst has rated the stock with a sell rating, six have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Editas Medicine has an average rating of “Hold” and an average price target of $26.73.

A number of large investors have recently modified their holdings of EDIT. State Street Corp lifted its stake in Editas Medicine by 305.4% in the 2nd quarter. State Street Corp now owns 537,640 shares of the company’s stock valued at $9,022,000 after purchasing an additional 405,022 shares during the last quarter. American Century Companies Inc. acquired a new stake in Editas Medicine in the 3rd quarter valued at about $7,497,000. Ark Investment Management LLC lifted its stake in Editas Medicine by 121.9% in the 2nd quarter. Ark Investment Management LLC now owns 510,187 shares of the company’s stock valued at $8,561,000 after purchasing an additional 280,265 shares during the last quarter. Northern Trust Corp lifted its stake in Editas Medicine by 245.9% in the 2nd quarter. Northern Trust Corp now owns 373,149 shares of the company’s stock valued at $6,261,000 after purchasing an additional 265,273 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Editas Medicine by 12.5% in the 2nd quarter. Vanguard Group Inc. now owns 2,177,146 shares of the company’s stock valued at $36,533,000 after purchasing an additional 241,973 shares during the last quarter. Institutional investors and hedge funds own 65.70% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://theolympiareport.com/2018/01/04/editas-medicine-inc-edit-insider-sells-512079-25-in-stock.html.

Editas Medicine Company Profile

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Insider Buying and Selling by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.